<DOC>
	<DOC>NCT01366365</DOC>
	<brief_summary>This double-blind, randomized, two-cohort, placebo-controlled, parallel group study characterized the pharmacokinetics, safety, and tolerability of MNTX following single doses and at steady-state during multiple dosing and assessed the effects of aging on the pharmacokinetics, safety and tolerability of MNTX.</brief_summary>
	<brief_title>Study of Pharmacokinetics, Safety and Tolerability of Intravenous Methylnaltrexone Bromide</brief_title>
	<detailed_description />
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<mesh_term>Methylnaltrexone</mesh_term>
	<criteria>1. Healthy Males and females who were between the ages of 18 and 45 years and healthy males and females who were 65 years of age and older. 2. Subjects who were nonsmokers 3. Subjects with body weights within range of 70100 kg (154220 lbs). 1. Subjects who had previously been exposed to MNTX 2. Subjects with a history of vasovagal episodes or fainting within the past five years 3. Subjects with a history of psychiatric or neurologic disorder 4. Subjects with a history of narrowangle glaucoma or intraocular hypertension 5. Subjects who had tested positive for hepatitis B surface antigen, IgM hepatitis B core antibody, hepatitis C antibody, or HIV 6. Subjects who have had a diagnosis of alcohol or substance dependence.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>